MPS Ltd Reports Record FY26 Profit, Sets Ambitious Growth Targets

Consolidated Revenue: INR 768.37 crore (+5.71%)
PAT: INR 173.22 crore (+16.32%)

Reader Takeaway: Strong FY26 performance and margin expansion; focus on integration and growth amidst acquisition strategy.

What just happened

MPS Limited has announced its financial results for the fiscal year 2026, marking it as the most profitable year on record. The company reported a consolidated revenue of INR 768.37 crore, an increase of 5.71% year-on-year. Profit After Tax (PAT) saw a significant jump of 16.32% to INR 173.22 crore, with Earnings Per Share (EPS) reaching INR 102.11. The EBITDA also grew by 11.83% to INR 235.85 crore, with margins expanding by 170 basis points to 30.7%.

Why this matters

This record profitability and strong margin expansion demonstrate MPS Ltd's operational efficiency and strategic execution. The company's decision not to pay a final dividend, instead prioritizing reinvestment in acquisitions like Unbound Medicine and a robust pipeline, signals a strong focus on aggressive growth. This strategy aims to achieve substantial future revenue and EBITDA targets.

The backstory

MPS Limited operates across three key segments: Research Solutions (60% of revenue), Education Solutions, and Corporate Learning. The company has been actively integrating acquisitions such as AJE and Unbound Medicine, and consolidating brands like Liberate Global under 'Liberate Global'. The management views the company as a platform serving knowledge markets, leveraging content engineering, platform technology, and AI.

What changes now

The company has set an ambitious guidance for FY27 EBITDA at over INR 300 crore, considering it a 'floor'. The long-term vision is to achieve INR 1,500 crore in revenue by FY28, maintaining margins around 30%. This aggressive growth plan necessitates continued focus on successful integration of acquired entities and organic expansion.

Risks to watch

Key risks include the successful integration of recent and future acquisitions, such as Unbound Medicine, to realize targeted synergies. There is also an ongoing market risk of clients potentially insourcing services, though MPS mitigates this through deep customer relationships and complex platforms.

Peer comparison

While specific peer data is not provided in the filing, MPS's reported ROCE of 38.2% indicates strong capital efficiency compared to industry averages. Competitors would likely be in the content engineering, publishing services, and knowledge management sectors.

Context metrics (time-bound)

• FY26 Revenue: INR 768.37 crore (+5.71% YoY)
• FY26 EBITDA: INR 235.85 crore (+11.83% YoY)
• FY26 EBITDA Margin: 30.7% (up 170 bps)
• FY26 PAT: INR 173.22 crore (+16.32% YoY)
• FY26 EPS: INR 102.11 (+16.31% YoY)
• FY27 EBITDA Guidance: > INR 300 crore
• FY28 Revenue Target: INR 1,500 crore

What to track next

Investors should closely monitor the integration progress of acquired companies, the company's ability to meet its FY27 EBITDA guidance, and sustained margin performance in the evolving market landscape.